Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Tarcocimab (KSI-301) in Wet age-related macular degeneration . The expected timing is based on the latest available company guidance and may change.
DAZZLE & DAYLIGHT study: 2/23/22- Topline data, did not meet primary endpoint. 7/24/23- Ph3 study met primary endpoints. Decided to discontinue the program. Presentation at The Retina Society '23. 03/31/26:- Zenkuda wet AMD now BLA-ready; DAYLIGHT successful; DAYBREAK Phase 3 topline one-year data expected in Q3 2026. 05/07/26:- Zenkuda wet AMD remains BLA-ready; DAYBREAK Phase 3 topline one-year data still expected in third quarter 2026. 08/13/26:- DAYBREAK one-year Phase 3 topline data for Zenkuda will be reported in September 2026.
Verification
Confirm timing and program details against the company announcement or filing.